Status message

Active context: kki_bg_colors_yellow

A Randomized, Double-Blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Principal Investigator:

To evaluate the efficacy and safety of dasotraline (4mg/day and 6 mg/day) compared with placebo in adult subjects with ADHD as measured by change from baseline at Week 8 in ADHD symptoms assessed using the ADHD Rating Scale Version IV (ADHD RS-IV) with adult prompts total score.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.